Bioventix PLC (AIM:BVXP)

Market Cap	135.19M
Revenue (ttm)	13.61M
Net Income (ttm)	8.10M
Shares Out	5.22M
EPS (ttm)	1.53
PE Ratio	16.94
Forward PE	15.15
Dividend	1.55 (5.98%)
Ex-Dividend Date	Nov 7, 2024

Volume	7,033
Average Volume	6,152
Open	2,581.00
Previous Close	2,590.00
Day's Range	2,552.00 - 2,650.00
52-Week Range	2,552.00 - 4,800.00
Beta	0.42
RSI	35.25
Earnings Date	Mar 25, 2025

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 17
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVXP

Financial Performance

In 2024, Bioventix's revenue was 13.61 million, an increase of 6.17% compared to the previous year's 12.82 million. Earnings were 8.10 million, a decrease of -3.29%.